Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 28,344 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,374 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,687 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 28,35 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,4 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,7 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 108,95 mg aktiv substans